Total synthesis of the actinoallolides and a designed photoaffinity probe for target identification. by Anketell, Matthew et al.
Journal Name
Total Synthesis of the Actinoallolides and a Designed
Photoaffinity Probe for Target Identification†
Matthew J. Anketell, Theodore M. Sharrock and Ian Paterson∗
The actinoallolides are a family of polyketide natural products isolated from the bacterium
Actinoallomurus fulvus. They show potent biological activity against trypanosomes, the causative
agents of the neglected tropical diseases human African trypanosomiasis (sleeping sickness)
and Chagas disease, while exhibiting no cytotoxicity against human cell lines. Herein, we give
a full account of our strategy evolution towards the synthesis of this structurally unique class of
12-membered macrolide, which culminated in the first total synthesis of (+)-actinoallolide A in 20
steps and 8% overall yield. Subsequent late-stage diversification then provided ready access to
the congeneric (+)-actinoallolides B-E. Enabled by this flexible and efficient endgame sequence,
we also describe the design and synthesis of a photoaffinity probe based on actinoallolide A to
investigate its biological mode of action. This will allow ongoing labelling studies to identify their
protein binding target(s).
Introduction
Among communicable illnesses, parasitic diseases are the fourth
largest cause of mortality worldwide, being responsible for over
500,000 deaths in 2015.1,2 Two such conditions are the neglected
tropical diseases human African trypanosomiasis (sleeping sick-
ness)3–5 and Chagas disease,6–10 both caused by protozoan par-
asites of the genus Trypanosoma. These illnesses are estimated to
account for a loss of 455,000 disability-adjusted life years annu-
ally.11 Trypanosomes are extremely adept at evading the immune
system, and these neglected tropical diseases can only be cleared
from the body with the help of chemotherapeutic agents.12 How-
ever, the ongoing development of effective pharmaceutical agents
against the causative agents of these diseases has been challeng-
ing due to two major factors.13,14 First, the eukaryotic nature
of protozoan parasites means that trypanosomes are biologically
more closely related than bacteria to human cells. This renders
the development of selective anti-trypanosomal drugs more chal-
lenging.15 Secondly, as these diseases mainly affect less economi-
cally developed countries, a lack of financial incentive to develop
new drugs has led to an urgent need for better, more effective and
safer treatments for these neglected diseases.16
Fortunately, the natural world possesses a rich and structurally
diverse source of antiparasitic compounds.17 The actinoallolides
(Fig. 1), a family of novel polyketides, are one such exam-
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Fig. 1 3D structures of the five actinoallolide congeners 1-5 and the
designed photoaffinity probe analogue 6
ple, isolated by Iwatsuki and co-workers from a cultured strain
(MK10-036) of the actinomycete bacterium Actinoallomurus ful-
vus, obtained from the roots of Capsicum fruitescens collected in
Thailand.18 The 3D structure of actinoallolide A (1) was deter-
mined by spectroscopic analysis and X-ray crystallography, which
revealed the presence of 10 stereocentres, two trisubstituted
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alkenes and a 12-membered macrolactone incorporating a five-
membered hemiacetal. In addition, the structures of actinoal-
lolides B-E (2-5) were confirmed by chemical correlation with
actinoallolide A.
The actinoallolides were tested against three strains of Try-
panosoma and compared with several commonly used antitry-
panosomal drugs. Actinoallolides A-E were also tested for biolog-
ical activity against Trypanosoma brucei brucei, the strain respon-
sible for animal trypanosomiasis (Nagana disease) and compared
with three of the most commonly used drug treatments. They
all compared favourably, with actinoallolide A determined as the
most potent by two orders of magnitude, with an IC50 of 8.3 nM.
Actinoallolide A (1) was also tested against Trypanosoma brucei
rhodesiense, a strain responsible for human African trypanosomia-
sis and Trypanosoma cruzi, the causative agent of Chagas disease,
showing double the potency of benznidazole. Actinoallolide A (1)
showed no observable activity against MRC-5 human cells, giving
it a high selectivity index (>20,000).19 It was inactive against
Gram-positive and negative bacteria and against yeast and fungi,
indicating a highly specific mechanism of antitrypanosomal activ-
ity that is yet to be determined.
The isolation group have also identified the actinoallolide
biosynthetic gene cluster, proposed a biosynthesis,20 and re-
ported preliminary synthetic studies.21 Herein, we give a full ac-
count of the first total synthesis of the actinoallolides,22 which
was enabled by a challenging ring-closing metathesis reaction to
form the macrocyclic trisubstituted alkene, the most complex ex-
ample of its kind.23 As the biological target and mechanism of
action of the actinoallolides are unknown, we sought to lever-
age our total synthesis to shed light on these unanswered ques-
tions. Based on a highly efficient endgame, we now report the
design and synthesis of the actinoallolide A-based probe 6 for tar-
get identification using photoaffinity labelling.24,25
Results and discussion
Retrosynthetic analysis of actinoallolide A
Our proposed key bond disconnections (Scheme 1) were of the
C1 ester and the C8-C9 alkene to form two fragments of roughly
equal size and complexity: the macrocycle precursor 7 and the
side chain 8. A major advantage of this approach is that it allows
a flexible fragment coupling strategy whereby the two coupling
steps could be undertaken in either order; cross metathesis could
be followed by macrolactonisation, or esterification could be fol-
lowed by ring-closing metathesis as desired.
The C1-C8 fragment 7 would be forged from natural (S)-lactic
acid with key bonds formed via a Seebach alkylation and a di-
astereoselective aldol reaction. Protection of the C3 and C6 al-
cohols would allow late-stage unmasking of the delicate five-
membered hemiacetal after deprotection and oxidation at C3 to
give actinoallolide A.
The side chain contains two distinct stereoclusters. The C11-
C14 stereotetrad was envisaged to be constructed by a substrate-
controlled allylation of 9 preceded by a lactate aldol reaction to
reveal, after redox adjustment, ester 10. The isolated C14 stere-
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Scheme 1 Initially proposed retrosynthesis of actinoallolide A with the
three key aldol reactions highlighted in green
arrangement from the diester 11. The ‘all syn’ stereotetrad in
12 can then be formed by a titanium-mediated aldol reaction/in
situ reduction between methacrolein and ethyl ketone 13, itself
synthesised in three steps from (R)-Roche ester (14). The deci-
sion to attach the terminal ethyl group at such a late stage was
made in order to form the C21 ketone as late as possible to fa-
cilitate late-stage diversification. A more complex organometallic
reagent could be used to add any modified tail in place of the
ethyl group.
Finally, the decision to utilise two sets of orthogonal protecting
groups was informed by our planned endgame. The hydroxyl
groups at C21 and C3 require oxidation, whereas those at C6,
C13 and C19 do not. Thus it was planned to use benzyl ether-
based groups for the former and silyl ethers for the latter hydroxyl
groups.
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Scheme 2 Synthesis of the side chain fragment 8
Synthesis of the C9-C21 side chain fragment (8)
The synthesis of side chain fragment 8 commenced with ethyl ke-
tone 13.26 In previous work, the ‘all-syn’ aldol selectivity required
for the construction of 12 had been achieved by use of tin (II)
triflate as a Lewis acid.27,28 While effective, the use of tin(II) tri-
flate was procedurally cumbersome, especially on scale owing to
its capricious preparation. We sought to improve upon this pro-
cess by combining two recent developments in aldol chemistry.
Romea and Urpí have reported the use of titanium Lewis acids
for the highly selective aldol reactions of protected β -hydroxy ke-
tones29 and α-hydroxy ketones with an in situ reduction to afford
the syn-1,3-diol.30 It was reasoned that combining these two pro-
cesses would afford the desired ‘all-syn’ stereotetrad in diol 12.
In the event, application of this in situ reduction with LiBH4 to
the aldol addition of ketone 13 and methacrolein provided diol
12 in 90% yield as a single diastereomer (Scheme 2). Owing to
the oxophilicity of the titanium and boron complexes formed in
the reaction, an extended workup incorporating treatment with
hydrogen peroxide and multiple washings with Rochelle salt so-
lution was found to be necessary for release of 12.
After selective monoesterification of the allylic alcohol in diol
12 was found to be problematic, it was decided to proceed
through the required Ireland-Claisen rearrangement31 with di-
ester 11. Only the O17 ester was correctly positioned to undergo
the [3,3]-sigmatropic rearrangement while the O19 ester would
be removed during the later reduction of the C13 methyl ester to
the aldehyde. Guided by a similar Ireland-Claisen rearrangement
used in the total synthesis of ebelactone,32 we began investigat-
ing this key step. Initial attempts at performing this reaction led
to appreciable formation of the C14 α-silylated by-product. This
TMS group could be removed with K2CO3 in MeOH but, as would
be expected, led to significant epimerisation. The epimer was
visible by NMR and provided evidence that the Ireland-Claisen
product had been obtained as a single diastereomer. This side
reaction is proposed to occur via enolisation of the formed silyl
ester by excess LDA and trapping of this enolate with TMSCl. As
such, it was important to precisely control the equivalents of LDA
used. In order to avoid quenching any LDA, it is necessary to re-
move all traces of HCl from the large excess of TMSCl used. In
the ebelactone work, this was accomplished by premixing TMSCl
with Et3N and centrifuging the resulting suspension to remove
the precipitate. In this work, removal of the precipitate was more
conveniently accomplished via filtration through a syringe tip fil-
ter (PVDF membrane, 0.45 µm pores). Optimising the quantity
of LDA used increased the yield to 73% with no observable for-
mation of the α-silylated by-product. For ease of isolation, the
carboxylic acid product was methylated without purification to
afford methyl ester 10.
Pleasingly, the DIBAL-H reaction of this ester 10 proceeded
well, reducing the methyl ester at C13 to the corresponding alde-
hyde and liberating the free hydroxyl group at C19, setting the
stage for the second strategic aldol reaction. While substrate con-
trol was used to construct all other stereocentres in side chain
fragment 8, the anticipated mismatch between the Felkin-Anh
selectivity of aldehyde 15 and the desired configuration at the
C13 hydroxyl stereocentre made it impossible in this case. Us-
ing boron aldol methodology developed in the group,33,34 we
were able to couple aldehyde 15 with lactate-derived ketone 16
to form anti adduct 17 as a single diastereomer, overriding the
inherent facial selectivity of aldehyde 15 to install the C12 and
C13 stereocentres. Protection of both hydroxyl groups as TES
ethers then afforded 18 which underwent a standard two-step
auxiliary removal procedure to provide aldehyde 9.33 Addition
of the allyl moiety to 9 to complete the side chain fragment 8 re-
quired some optimisation with the use of allylmagnesium chloride
or allyltrimethylsilane leading to low diastereoselectivity. Fortu-
nately, it was found that the utilisation of allyltributylstannane in
a Hosomi-Sakurai reaction35,36 with the non-chelating Lewis acid
BF3·OEt2 afforded 8 in high yield with 15:1 dr.
This completed the scalable and high-yielding synthesis of the
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Scheme 3 Synthesis of the key propyl ketone 22 and attempts at elaboration
side chain fragment 8 in 13 linear steps from (R)-Roche ester (14)
with an overall yield of 21%. This excellent yield (an average of
89% per step) and the scalability of the route allowed 2.3 g to
be prepared, providing ample material for development of the
endgame.
Synthesis of the C1-C8 macrocycle precursor fragment
The synthesis of the macrocycle precursor fragment began with
the construction of dioxolanone 19 via a two-step procedure
(Scheme 3),37 allowing an enolate alkylation38 with methallyl
bromide to install the C6 stereocentre. This reaction proved dif-
ficult to optimise, with a 53% yield of 20, albeit as a single di-
astereomer. This was due to formation of a major by-product due
to self-reaction of the dioxolanone.39 However, the modest yield
was deemed sufficient and allowed the preparation of 20 on a
multi-gram scale.
The removal of the pivaldehyde-derived auxiliary via ring open-
ing of dioxolanone 20 was the next task to be accomplished.
In preliminary studies, the desired conversion to propyl ketone
22 was achieved using a four-step sequence commencing with
ring opening to the methyl ester. We envisaged abridging this
sequence by using a different ring-opening procedure. The first
attempt to convert the dioxolanone to the propyl ketone directly
by addition of propylmagnesium bromide, however, was unsuc-
cessful, yielding either unreacted starting material or the double
addition product. Ring opening to the Weinreb amide 21 was
trialled next and proceeded in excellent yield using the in situ
generated anion of N,O-dimethylhydroxylamine. With this result,
a one-pot conversion to the desired propyl ketone was examined.
However, the conversion of 21 to the corresponding propyl ketone
in situ proved unsuccessful even with warming to room tempera-
ture. Weinreb amide 21 was next silyl protected and converted to
propyl ketone 22, required for the planned C3-C4 bond-forming
lithium-mediated aldol reaction. As the protecting group strat-
egy utilised a silyl group at C6 and a PMB group at C3, the C1
protecting group was required to be orthogonal to both.
From propyl ketone 22, two routes to macrocycle precursor
fragment 7 were initially considered. The first plan was to utilise
an orthoester protecting group on aldehyde 23, as this would al-
low access to C1 at the desired carboxylic acid oxidation level.
This lithium-mediated aldol reaction afforded syn adduct 24, pro-
viding the desired diastereomer in good yield and with useful di-
astereoselectivity. We had planned to protect the C3 alcohol with
a PMB group, however all attempted conditions led to no reac-
tion or to degradation, presumably owing to steric congestion.
Furthermore, removal of the orthoester protecting group could
not be achieved without degradation due to the acid and base
sensitivity of the aldol adduct.
With this approach proving to be unviable, C1 was next in-
troduced at the protected alcohol oxidation state. Noting that
PMB groups can be oxidatively transposed,40 this second plan
was to utilise a PMB group on aldehyde 25 to produce aldol
adduct 26. As before, the lithium-mediated aldol reaction af-
forded the syn adduct in good yield, in a 4:1 ratio of diastere-
omers. The major diastereomer was then converted to PMP acetal
27 by treatment with DDQ under anhydrous conditions. Disap-
pointingly, subsequent attempts at reductive PMP opening to the
primary alcohol were all unsuccessful, with the use of DIBAL-H40
or NaCNBH3/TMSCl
41 causing side-reactions or reacting with the
undesired regioselectivity to revert to secondary alcohol 26. This
unexpected selectivity may be due to preferrential chelation of
the Lewis acid between the C3 oxygen and the ketone rather than
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Scheme 4 Completion of the synthesis of macrocycle precursor fragment 37
the less hindered C1 oxygen as would normally be expected.
Given that this selectivity problem was likely due to the propen-
sity of the C5 ketone to coordinate with the adjacent C3 oxygen,
it was proposed that reducing the C5 ketone and transiently pro-
tecting the resulting alcohol as a TMS ether might circumvent this
impasse. Ketone 27 was thus reduced using LiBH4 to form sec-
ondary alcohol 28 in 70% yield and 2:1 dr. The diastereomers
were inseparable by chromatography so the alcohols were then
silylated to form 29. This mixture of diastereomeric PMP acetals
then underwent reductive opening with DIBAL-H. Surprisingly,
the two epimeric acetals reacted with opposing regioselectivities,
with the major diastereomer forming the undesired secondary al-
cohol 30 and the minor diastereomer forming the desired primary
alcohol 31.
In light of this mixed result, it was reasoned that if we could
override the inherent substrate selectivity of ketone 27 to re-
duction, and obtain the 1,3-anti diastereomer selectively, this
might provide a viable route to the macrocycle fragment. Test-
ing a range of simple reducing agents was fruitless, with each
one either giving the undesired selectivity or no reaction. It was
next decided to attempt the reduction of the C5 ketone prior
to PMP acetal formation, using the C3 alcohol in 26 to direct a
1,3-anti Evans-Tishchenko42 or Evans-Saksena reduction.43 With
prolonged reaction time and an excess of the samarium cata-
lyst,42 it was possible to achieve a low yield of 10% with 2:1
dr for the former reaction, but no product was obtained under
the latter conditions. This was attributed to the steric hindrance
of the C5 ketone with its quaternary α stereocentre incorporating
a bulky OTMS group.
These frustrations en route to the macrocycle precursor frag-
ment led us to consider more substantial modifications to the
route. The efforts thus far had focused on installing a PMB pro-
tecting group at C3, either by a ‘PMB transposition’ of the PMB
group at C1, or by direct protection of the alcohol at C3. The
former method had failed due to the selectivity problems with
opening the intermediate PMP acetal and the latter had failed
due to the steric hindrance of aldol adduct 26 and its insta-
bility under forcing conditions. To circumvent these problems
within the constraints of the overall protecting group strategy -
that is to allow for the chemoselective oxidative removal of the
C3 and C21 protecting groups in one operation, it was proposed
to switch the C3 protecting group from PMB to PMBM (para-
methoxybenzyloxymethyl).44 Like the PMB group, it can be ox-
idatively removed orthogonally to silyl groups but can be installed
under far milder conditions. However, as the PMBM group was
liable to cleavage under oxidative conditions, this alteration nec-
cessitated a revision of the C1 protecting group such that it could
be removed orthogonally to the PMBM group. Given that the aro-
matic ring in the DMB (3,4-dimethoxybenzyl)45 group is more
electron rich than in the PMBM group, it was anticipated that se-
lective oxidative cleavage of the DMB group would be possible.46
The corresponding DMB-protected aldehyde 32 required for
the aldol coupling was prepared via a three-step procedure.47
This aldehyde then underwent an analogous lithium-mediated
aldol reaction with propyl ketone 22, providing syn adduct 33
(Scheme 4) in similar yield and dr to that obtained from the PMB-
protected variant. This was subsequently PMBM protected using
the mild base DIPEA in refluxing acetonitrile overnight to afford
PMBM ether 34 in excellent yield. With triply-protected aldol
adduct 34 in hand, selective DMB cleavage was next attempted.
Fortunately, one equivalent of DDQ with careful monitoring af-
forded primary alcohol 35 in excellent yield, with complete reten-
tion of the PMBM group. This then underwent a double oxidation
sequence; first was a Swern oxidation to give aldehyde 36, then
a Pinnick oxidation provided the complete macrocycle precursor
fragment 37.
Overall, macrocycle precursor fragment 37 was synthesised in
10 linear steps from (S)-lactic acid with an overall yield of 17%.
This represents an average of 84% per step, and the scalability
of the route allowed 600 mg to be prepared, providing ample
material for development of the endgame.
Fragment union and endgame
With key fragments 8 and 37 in hand, the stage was set to explore
the pivotal fragment union sequence. The retrosynthetic plan
(Scheme 1) had left the ordering of these steps flexible. How-
ever, preliminary investigations had indicated that an efficient
and stereoselective cross metathesis to give the trisubstituted 8E
alkene was unlikely to succeed, so we proceeded with exploring
the esterification/RCM sequence. The fragments 37 and 8 were
coupled together under standard Yamaguchi conditions48 to af-
ford ester 38 in an excellent yield of 99%, enabling investigation
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Scheme 5 Fragment union and RCM-mediated formation of the 12-membered macrocycle 39
of the ”do-or-die” macrocycle-forming RCM step (Scheme 5).
The first attempt at cyclisation of 38 using Grubbs second-
generation catalyst (G-II)49,50 in refluxing degassed CH2Cl2 pro-
vided only the undesired dimer 40 in quantitative yield. (Table 1,
entry 1). Increasing the catalyst loading to 50 mol% (entry 2) or
the use of higher-boiling solvents (entries 3 and 4) failed to pro-
vide any macrocyclic product, in each case returning only dimer
40. As an additional measure, a solution of catalyst was added
portionwise over the initial few hours of the reaction to reduce
catalyst decomposition, although the colour change from pur-
ple to brown was observed within 30 min of each addition, in-
dicating rapid catalyst degradation. In light of these failures, we
switched to the more reactive Hoveyda-Grubbs second-generation
catalyst (HG-II).51,52 Gratifyingly, an initial RCM reaction of 38,
overnight in refluxing toluene, afforded an inseparable 1:1 mix-
ture of dimer 40 and desired macrocycle 39 (entry 5). Increasing
the catalyst loading to 40 mol% and the reaction time to 72 h in-
creased the product:dimer ratio to 1.5:1 (entry 6). In an attempt
to increase the reaction rate and yield, the solvent was changed
to o-xylene to allow reflux at a higher temperature. Surprisingly,
this led to a reduction in the product:dimer ratio to 1.2:1 (entry
9), indicating that there was a ‘sweet spot’ temperature at around
110 - 140 °C, below which the reaction is prohibitively slow and
above which catalyst decomposition occurs.
By this point, a mechanistic hypothesis was proposed whereby
the terminal alkene present in 38 rapidly dimerises. The ruthe-
nium catalyst can then reinsert into the new disubstituted alkene
in this dimer and can then undergo one of two processes. In most
cases, this undergoes an intermolecular reaction with another
molecule of dimer 40 to reversibly return to the dimer. Much
more slowly, but irreversibly, this ruthenium carbene can undergo
an intramolecular reaction with the 1,1-disubstituted alkene to
afford desired macrocycle 39. To help encourage the slow, irre-
versible RCM step, the duration of the reaction was increased to
seven days, increasing the product:dimer ratio to 3:1 and pro-
viding the desired product with an improved yield of 75% (entry
10). To our knowledge, this challenging and remarkable transfor-
mation is the most complex example of an RCM reaction to form
a trisubstituted alkene in a medium-sized ring.23
Having prepared an abundant supply of advanced intermedi-
ate 39, the removal of both PMB-containing protecting groups
was accomplished by treatment with DDQ, affording diol 41 in
94% yield (Scheme 6). Chemoselective oxidation of the pri-
mary alcohol at C21 in the presence of the C3 secondary alco-
hol was achieved using a TEMPO/BAIB oxidation53,54 which af-
Table 1 Screening of ring-closing metathesis conditions for the formation
of macrocycle 39 from precursor 38 (G-II = Grubbs second-generation
catalyst, HG-II = Hoveyda-Grubbs second-generation catalyst)
Entry Cat. (mol%) Solvent (mM) Temp. Time 39:40
1 G-II (20) CH2Cl2 (5) 40 °C 18 h 0:1
2 G-II (50) CH2Cl2 (10) 40 °C 18 h 0:1
3 G-II (20) Benzene (1) 80 °C 18 h 0:1
4 G-II (20) Toluene (1) 110 °C 18 h 0:1
5 HG-II (20) Toluene (1) 110 °C 18 h 1:1
6 HG-II (40) Toluene (1) 110 °C 72 h 1.5:1
7 HG-II (40) Toluene (10) 110 °C 72 h 1.3:1
8 HG-II (40) Toluene (0.25) 110 °C 72 h 2:1
9 HG-II (40) Xylene (0.25) 145 °C 72 h 1.2:1
10 HG-II (40) Toluene (1) 110 °C 7 d 3:1
forded aldehyde 42 in 90% yield. Subsequently, chemoselective
addition of ethylmagnesium bromide to the newly formed alde-
hyde in the presence of the C5 ketone proceeded smoothly, af-
fording an inseparable epimeric mixture of 43 in 91% yield, with
no observable attack at the ketone.
Having completed the full carbon backbone of the actinoal-
lolides, our attention now turned to the final two steps of oxi-
dation and global deprotection. Oxidation of both secondary al-
cohols at C3 and C21 was initially attempted under Swern con-
ditions, however, this was found to be unreliable. Alternatively,
the oxidation was performed using the milder Dess-Martin perio-
dinane.55 Double oxidation under these conditions was found to
be clean and reliable, providing triketone 44 in 99% yield.
The only obstacle now remaining was the final deprotection.
The conditions should ensure complete cleavage of the C6 TMS
ether and the C13 and C19 TES ethers, while also forming the
transannular hemiacetal. The conditions were also required to be
sufficiently mild to avoid any possible deleterious side reactions.
Preliminary experience with the lability of the hemiacetal motif
led to the hypothesis that actinoallolides C-E may be artefacts of
the elaborate chromatographic isolation process. Consequently,
we were particularly cautious to avoid elimination across the C3-
C4 bond and transesterification of the macrolactone in 44. Ini-
tial attempts using TBAF were unsuccessful, leading either to in-
complete deprotection or degradation. Pleasingly, acidic fluorous
deprotection conditions proved successful, with treatment of 44
with a 1:3 mixture of HF·py/py with warming to 40 °C effecting
quantitative conversion to (+)-actinoallolide A (1). The resulting
synthetic actinoallolide A possessed comparable specific rotation
and identical NMR spectra to those of the natural product (see
the ESI).
The total synthesis of (+)-actinoallolide A (1) was thus
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Scheme 6 Endgame and completion of the total synthesis of actinoallolide A (1)
achieved in 20 linear steps from (R)-Roche ester (14) with an
overall yield of 8%, representing an average yield of 88% per
step. Importantly, this first total synthesis gave an orthogonal
validation of the full 3D structure and absolute configuration of
actinoallolide A and will enable further biological investigations
of this highly potent family of natural products.
Conversion of actinoallolide A to actinoallolides B-E
We next sought to access the other four congeners, actinoallolides
B-E (2-5), by replication of the conversion protocols in the isola-
tion paper (Scheme 7).18 Actinoallolide A (1) underwent a 1,3-
syn hydroxyl-directed reduction using triethylborane followed by
sodium borohydride to afford actinoallolide B (2) in 93% yield
and as a single diastereomer. Subsequent treatment of actinoal-
lolide B (2) with trifluoroacetic acid caused dehydration of the
cyclic hemiacetal to provide actinoallolide D (4) in 99% yield.
During the initial purification of actinoallolide A using sil-
ica chromatography, some minor by-product formation was ob-
served. Using alumina instead, attempted purification of acti-
noallolide A led to conversion to a 1:1 mixture of actinoallolide C
(3) and actinoallolide E (5). This unexpected result indicated the
instability of the cyclic hemiacetal moiety to basic conditions, per-
haps explaining why global deprotection was unsuccessful under
basic fluorous conditions. This spontaneous conversion of acti-
noallolide A (1) to actinoallolides C (3) and E (5) on alumina
also provides evidence that these compounds are isolation arte-
facts rather than genuine natural products. This serendipitous
result completed our synthesis of all five members of the acti-
noallolides.
Based on the assumption that actinoallolides C and E are iso-
lation artefacts, it is likely that actinoallolide D is also an arte-
fact, arising from dehydration of actinoallolide B. This would
leave actinoallolides A and B as the only true natural products,
differing only in the oxidation level at C21. In examining the pro-
posed biosynthesis of actinoallolide A,20 the authors had iden-
tified an inactive ketoreductase domain (KR1) in the polyketide
synthase responsible for the biosynthesis of actinoallolide A. They
commented that “although KR1 has catalytic amino acids and the
NADPH binding motif, it seems to be inactive, as predicted from
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Scheme 7 Conversion of actinoallolide A (1) to actinoallolides B-E (2-5)
rather than being inactive, the KR1 domain were instead partially
active, this identified polyketide synthase would be able to gener-
ate both actinoallolides A and B. When the KR1 domain performs
the C21 reduction, actinoallolide B, containing the C21 alcohol, is
produced, and when transfer to module 2 occurs before the re-
duction can take place, the product is instead actinoallolide A,
with the unreduced C21 ketone. On inspection of the amino acid
sequence of the KR1 domain, it possesses both sets of character-
istic amino acids which determine whether reduction affords the
L- or D- configuration, potentially explaining its partial inactivity.
Synthesis of an actinoallolide A photoaffinity probe analogue
Having achieved a practical, convergent and high-yielding total
synthesis of the actinoallolides, we moved onto the design and
synthesis of a photoaffinity probe analogue (Scheme 8) to identify
their biological target. In order to minimally perturb the structure
of the native natural product, the photoaffinity probe 6 was cho-
sen to extend from the C23 terminus.56 The photoreactive moi-
ety is a diazirine, decomposing to a highly-reactive carbene upon
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irradiation at 365 nm, facilitating cross-linking to the bound tar-
get protein. The functional handle is a terminal alkyne, allowing
the facile conjugation of any desired reporter tag using a copper-
catalysed azide-alkyne cycloaddition.25
The synthesis of probe 6 began by intercepting the advanced
intermediate 42. In the total synthesis, addition of an ethyl group
was required to complete the actinoallolide carbon skeleton. In-
stead, the addition of the Grignard reagent derived from halide
45 afforded diol 46 in 69% yield as an inconsequential 1:1 mix-
ture of diastereomers. Chemoselective removal of the alkynyl
TMS group was achieved by treatment with AgNO3 and gave 47
in 65% yield. Next, a copper-catalysed azide-alkyne cycloaddition
between alkyne 47 and linker fragment 48 (prepared from 1,4-
cylohexanedione in eight steps)57 proceeded to afford triazole 49
(99%).
The EDCI/DMAP-mediated amidation of 49 with propargy-
lamine proceeded smoothly, affording amide 50 in 99% yield.
This amide then underwent a double DMP-mediated oxidation
to afford triketone 51 (93%). Finally, global deprotection un-
der acidic fluorous conditions proceeded with an excellent yield
of 99%, cleaving all three silyl ethers and inducing formation of
the transannular five-membered hemiacetal to form photoaffinity
probe 6. To date, this route has provided 26 mg of 6, sufficient
material for the required photoaffinity experiments. In prelim-
inary studies, the biological activities of synthetic actinoallolide
A (1) and photoaffinity probe 6 have been confirmed and pho-
toaffinity studies are currently ongoing.
Conclusions
This account details the first total synthesis of the actinoallolides,
a family of polyketide natural products prized for their promis-
ing anti-trypanosomal properties.58 This feat has been accom-
plished in a scalable, high-yielding and stereoselective fashion,
giving actinoallolide A (1) in 20 linear steps from (R)-Roche ester
(14) with an overall yield of 8%. This was achieved in a highly
convergent manner, utilising two fragments 8 and 37 of similar
complexity, which were obtained in 13 and 10 steps respectively.
The stubbornness of C3 manipulation to standard ‘PMB transpo-
sition’ conditions was frustrating and neccessitated modifications
to the original strategy. Fortunately, the judicious choice of alter-
native protecting groups allowed us to overcome this obstacle.
Fragment union was accomplished by esterification followed
by a highly challenging ring-closing metathesis, gratifyingly form-
ing the macrocyclic trisubstituted alkene as a single geometrical
isomer. This ”do-or-die” transformation required significant op-
timisation and is the most complex example of its kind. A high-
yielding endgame finally afforded actinoallolide A. Actinoallolide
A was then converted to actinoallolides B-E, completing the to-
tal synthesis of the entire natural product family. The alumina-
mediated conversion of actinoallolide A to actinoallolides C and E
provides evidence that actinoallolides C-E are isolation artefacts,
with actinoallolides A and B as the only true natural products.
On review of the biosynthetic data for the actinoallolides, a par-
tially active ketoreductase domain in the actinoallolide A polyke-
tide synthase has been postulated to be responsible for generating
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Scheme 8 Diversion of advanced intermediate 42 towards the synthesis
of photoaffinity probe analogue 6 of actinoallolide A
With the secondary aim of probing how actinoallolide A ex-
erts its highly specific biological effects, this route was diverted
to give 6 as a designed photoaffinity probe. This was achieved
8 | 1–10Journal Name, [year], [vol.],
in six steps from advanced intermediate 42. Ongoing work is fo-
cused on using 6 in various assays with the aim of identifying the
biological target of actinoallolide A. Identification of this target
and knowledge of the mechanism of action may allow the gen-
eration of simplified, more synthetically tractable or more potent
actinoallolide analogues in the ongoing effort to develop new, ef-
fective medicinal agents to treat neglected tropical diseases.
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